Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 022061
Company: MATRIX LABS

Products on NDA 022061

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE	LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE	150MG; 200MG; 300MG	TABLET; ORAL	None (Tentative Approval)	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 022061

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
10/21/2008	ORIG-1	Tentative Approval	Type 3 - New Dosage Form	STANDARD	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022061s000ltr.pdf